For your adult patients with 
generalized myasthenia gravis (gMG)

TWO TARGETED
TREATMENTS

MORE OPTIONS

UCB offers a unique portfolio of treatments targeting two distinct pathways for adults living with gMG, because no two patients are alike.1-3

 

UCB offers a unique portfolio of treatments targeting two distinct pathways for adults living with gMG, because no two patients are alike.1-3

RYSTIGGO is the first FcRn blocker approved for the treatment of adults with either anti-AChR Ab+ or anti-MuSK Ab+ gMG.1* Please see Important Safety Information for RYSTIGGO.

The precise mechanism through which RYSTIGGO exerts therapeutic effects in gMG is unknown.

Explore RystiggoHCP.com

Mechanism of Action

Clinical Trial Data

Safety

Dosing and Administration

ZILBRYSQ is the first and only self-administered complement C5 inhibitor approved for the treatment of adults with anti-AChR Ab+ gMG.2,4† Please see Important Safety Information for ZILBRYSQ.

The precise mechanism through which ZILBRYSQ exerts therapeutic effects in gMG is unknown.

Ab+=antibody positive; AChR=acetylcholine receptor; C5=complement component 5; FcRn=neonatal Fc receptor; MuSK=muscle-specific tyrosine kinase.

Explore RystiggoHCP.com 

Mechanism of Action

Clinical Trial Data

Safety

Dosing and Administration

Explore ZilbrysqHCP.com 

Mechanism of Action

Clinical Trial Data

REMS and Safety

Dosing and Administration

Ab+=antibody positive; AChR=acetylcholine receptor; C5=complement component 5; FcRn=neonatal Fc receptor; MuSK=muscle-specific tyrosine kinase.

No two patients with gMG are alike, and there remains a need for more treatment options4,5

More options mean more choices for providers to personalize treatment selection for their patients.

Gain insight behind UCB’s unique portfolio of treatments for gMG

Patients may experience debilitating gMG symptoms despite treatment6

Explore uncontrolled gMG

Personalizing gMG care relies on many key factors

Consider targeted treatment

FcRn and C5 play a role in gMG pathophysiology7

Discover distinct pathways

We’re committed to utilizing our expertise and rich history in neurology to help patients with gMG live the best life that they can.

UCB has dedicated 30 years to developing innovative solutions in neurology. For gMG, our focus is to help elevate the standard of care through a portfolio of targeted treatments to address patients' needs.

References:

  1. RYSTIGGO [Prescribing Information]. Smyrna, GA: UCB, Inc.
  2. ZILBRYSQ [Prescribing Information]. Smyrna, GA: UCB, Inc.
  3. MG treatment overview. Myasthenia Gravis Foundation of America. Accessed January 27, 2026. https://myasthenia.org/Treatments/Treatment-Overview
  4. Howard JF Jr, Bresch S, Genge A, et al; RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Neurol. 2023;22(5):395-406. doi:10.1016/S1474-4422(23)00080-7
  5. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383-394. doi:10.1016/S1474-4422(23)00077-7
  6. Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60(6):707-715. doi:10.1002/mus.26695
  7. Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front Neurol. 2020;11:538. doi:10.3389/fneur.2020.00538

IMPORTANT SAFETY INFORMATION FOR RYSTIGGO (rozanolixizumab-noli)

RYSTIGGO is associated with important warnings and precautions, including increased risk of infection, drug-induced aseptic meningitis, and hypersensitivity reactions. The most common adverse reactions (≥10%) in patients with gMG are headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea.

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING FOR ZILBRYSQ (zilucoplan)

ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for meningococcal bacteria at least 2 weeks prior to the first dose...

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING FOR ZILBRYSQ (zilucoplan) Injection

INDICATION

ZILBRYSQ (zilucoplan) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

  • Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ZILBRYSQ, unless the risks of delaying therapy outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccination against meningococcal bacteria in patients receiving a complement inhibitor.
  • Patients receiving ZILBRYSQ are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, ZILBRYSQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ZILBRYSQ REMS.

CONTRAINDICATIONS

ZILBRYSQ is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection.

WARNINGS AND PRECAUTIONS

Serious Meningococcal Infections

ZILBRYSQ, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of ZILBRYSQ treatment is contraindicated in patients with unresolved serious Neisseria meningitidis infection.

Complete or update meningococcal vaccination (for serogroups A, C, W, Y, and B) at least 2 weeks prior to administration of the first dose of ZILBRYSQ, according to current ACIP recommendations for patients receiving a complement inhibitor.

If urgent ZILBRYSQ therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible.

Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Consider interruption of ZILBRYSQ in patients who are undergoing treatment for serious meningococcal infection, depending on the risks of interrupting treatment in the disease being treated.

ZILBRYSQ REMS

Due to the risk of serious meningococcal infections, ZILBRYSQ is available only through a restricted program under a REMS called ZILBRYSQ REMS.

Under the ZILBRYSQ REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risk of serious meningococcal infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccines. Additional information on the REMS requirements is available at www.ZILBRYSQREMS.com or 1-877-414-8353.

Other Infections

Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported in patients treated with complement inhibitors. ZILBRYSQ blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Administer vaccinations for the prevention of Streptococcus pneumoniae infection according to ACIP recommendations. Patients receiving ZILBRYSQ are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.

Pancreatitis and Other Pancreatic Conditions

Pancreatitis and pancreatic cysts have been reported in patients treated with ZILBRYSQ. Patients should be informed of this risk before starting ZILBRYSQ. Obtain lipase and amylase levels at baseline before starting treatment with ZILBRYSQ. Discontinue ZILBRYSQ in patients with suspected pancreatitis and initiate appropriate management until pancreatitis is ruled out or has resolved.

ADVERSE REACTIONS

In a placebo-controlled study, the most common adverse reactions (reported in at least 10% of gMG patients treated with ZILBRYSQ) were injection site reactions, upper respiratory tract infections, and diarrhea.

Please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION AND INDICATION FOR RYSTIGGO (rozanolixizumab-noli)

INDICATION

RYSTIGGO (rozanolixizumab-noli) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

WARNINGS AND PRECAUTIONS

Infections: RYSTIGGO may increase the risk of infection. Delay RYSTIGGO administration in patients with an active infection until the infection is resolved. During treatment with RYSTIGGO, monitor for clinical signs and symptoms of infection. If serious infection occurs, administer appropriate treatment and consider withholding RYSTIGGO until the infection has resolved.

Immunization

Immunization with vaccines during RYSTIGGO treatment has not been studied. The safety of immunization with live or live-attenuated vaccines and the response to immunization with any vaccine are unknown. Because RYSTIGGO causes a reduction in IgG levels, vaccination with live-attenuated or live vaccines is not recommended during treatment with RYSTIGGO. Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with RYSTIGGO.

Aseptic Meningitis: Serious adverse reactions of aseptic meningitis (also called drug-induced aseptic meningitis) have been reported in patients treated with RYSTIGGO. If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema and rash, were observed in patients treated with RYSTIGGO. Management of hypersensitivity reactions depends on the type and severity of the reaction. Monitor patients during treatment with RYSTIGGO and for 15 minutes after for clinical signs and symptoms of hypersensitivity reactions. If a reaction occurs, institute appropriate measures if needed.

ADVERSE REACTIONS

In a placebo-controlled study, the most common adverse reactions (reported in at least 10% of RYSTIGGO-treated patients) were headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea. Serious infections were reported in 4% of patients treated with RYSTIGGO. Three fatal cases of pneumonia were identified, caused by COVID-19 infection in two patients and an unknown pathogen in one patient. Six cases of infections led to discontinuation of RYSTIGGO.

Please see the full Prescribing Information.

UCB respects your privacy. Click here to manage your email preferences.

For US Healthcare Professionals Only.

RYSTIGGO® and ZILBRYSQ® are registered trademarks of the UCB Group of Companies. All other trademarks and registered trademarks are the property of their respective holders. 

©2026 UCB, Inc., Smyrna, GA 30080. All rights reserved.

US-RZ-2500510

UCB respects your privacy. Click here to manage your email preferences.

For US Healthcare Professionals Only.

RYSTIGGO® and ZILBRYSQ® are registered trademarks of the UCB Group of Companies. All other trademarks and registered trademarks are the property of their respective holders.

©2026 UCB, Inc., Smyrna, GA 30080. All rights reserved.

 

US-RZ-2500510